Summary: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.

Top Publications

  1. Sculier D, Gayet Ageron A, Battegay M, Cavassini M, Fehr J, Hirzel C, et al. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. BMC Infect Dis. 2017;17:476 pubmed publisher
    ..We aimed to determine the reasons for prescribing the rilpivirine (RPV)/tenofovir disoproxil (TDF)/emtricitabine (FTC) co-formulation within the Swiss HIV Cohort Study and to assess its effectiveness and safety over a 24 ..
  2. Hoagland B, Moreira R, De Boni R, Kallas E, Madruga J, Vasconcelos R, et al. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. J Int AIDS Soc. 2017;20:21472 pubmed publisher
    ..centres in Rio de Janeiro and São Paulo were evaluated for eligibility and offered 48 weeks of daily emtricitabine/tenofovir for PrEP...
  3. . Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016;16:565-575 pubmed publisher
    ..virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI; efavirenz or nevirapine)...
  4. Todesco E, Surgers L, Marcelin A, Calvez V, Meynard J, Morand Joubert L. Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen. J Acquir Immune Defic Syndr. 2016;72:e43-5 pubmed publisher
  5. Underhill K. Preexposure chemoprophylaxis for HIV prevention. N Engl J Med. 2011;364:1374; author reply 1374-5 pubmed publisher
  6. Gallay P, Chatterji U, Kirchhoff A, Gandarilla A, Gunawardana M, Pyles R, et al. Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. PLoS ONE. 2017;12:e0184303 pubmed publisher
    ..relationship of these agents was measured and showed that topical tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) can offer 100% protection against rectal or vaginal HIV challenges...
  7. Margot N, Wong P, Kulkarni R, White K, Porter D, Abram M, et al. Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide. J Infect Dis. 2017;215:920-927 pubmed publisher
    ..01%) and 7 had M184V/I (0.1%), despite high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and lamivudine and potential transmission of resistance to these drugs...
  8. DeJesus E, Ramgopal M, Crofoot G, Ruane P, Lamarca A, Mills A, et al. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, . Lancet HIV. 2017;4:e205-e213 pubmed publisher
    ..The coformulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently been approved, and we aimed to investigate the efficacy, safety, and ..
  9. Beyrer C, Bekker L, Pozniak A, Barré Sinoussi F. Pre-exposure prophylaxis works--it's time to deliver. Lancet. 2015;385:1482-4 pubmed publisher

More Information


  1. Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015;15:793-802 pubmed publisher
    ..and safety of efavirenz 400 mg compared with the standard 600 mg dose, combined with tenofovir and emtricitabine, as first-line HIV therapy...
  2. Spaulding A, Rutherford G, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2010;:CD008740 pubmed publisher
    ..different drugs in addition to TDF and AZT; one had lamivudine (3TC) and nevirapine (NVP) and the other had emtricitabine (FTC) and efavirenz (EFV)...
  3. Karim S, Kashuba A, Werner L, Karim Q. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378:279-81 pubmed publisher
  4. Abgrall S, Ingle S, May M, Costagliola D, Mercie P, Cavassini M, et al. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS. 2013;27:803-13 pubmed publisher
    ..Those on tenofovir/emtricitabine backbone had lowest rates of substitutions and switches to nonstandard regimen, and on abacavir/lamivudine ..
  5. Cohen M, Baden L. Preexposure prophylaxis for HIV--where do we go from here?. N Engl J Med. 2012;367:459-61 pubmed publisher
  6. Saag M. Preventing HIV in women--still trying to find their VOICE. N Engl J Med. 2015;372:564-6 pubmed publisher
  7. Celum C, Morrow R, Donnell D, Hong T, Hendrix C, Thomas K, et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med. 2014;161:11-9 pubmed publisher
    ..prophylaxis (PrEP) using the antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combination with emtricitabine (FTC-TDF) reduces the risk for HIV-1 acquisition...
  8. Corado K, Daar E. Emtricitabine + tenofovir alafenamide for the treatment of HIV. Expert Opin Pharmacother. 2017;18:427-432 pubmed publisher
    ..States Food and Drug Administration has now approved this drug coformulated with elvitegravir/cobicistat/emtricitabine, rilpivirine/emtricitabine and emtricitabine...
  9. Waitt C, Diliiy Penchala S, Olagunju A, Amara A, Else L, Lamorde M, et al. Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1060:300-307 pubmed publisher
    ..the validation and clinical application of a LC-MS/MS method for the quantification of lamivudine (3TC), emtricitabine (FTC) and tenofovir (TFV) in dried blood spots (DBS) and dried breast milk spots (DBMS)...
  10. Squillace N, Ricci E, Quirino T, Gori A, Bandera A, Carenzi L, et al. Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS ONE. 2017;12:e0179254 pubmed publisher
    ..was to evaluate the impact on Liver and Kidney toxicity of the single tablet regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF) on Antiretroviral Therapy (ART) experienced or naïve ..
  11. Mugwanya K, John Stewart G, Baeten J. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. Expert Opin Drug Saf. 2017;16:867-871 pubmed publisher
    ..Pre-exposure prophylaxis (PrEP) with daily oral tenofovir disoproxil fumarate (TDF)/emtricitabine is an attractive HIV prevention option for women who are lactating but data are limited on its safety during ..
  12. Grant R, Liegler T, Defechereux P, Kashuba A, Taylor D, Abdel Mohsen M, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29:331-7 pubmed
    Pre-exposure prophylaxis (PrEP) with daily oral emtricitabine (FTC)/tenofovir disoproxil fumarate may select for drug resistance if there is low adherence...
  13. Cressey T, Siriprakaisil O, Klinbuayaem V, Quame Amaglo J, Kubiak R, Sukrakanchana P, et al. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study. BMC Infect Dis. 2017;17:496 pubmed publisher
    ..1:1:1) among three groups to receive a controlled number of TDF (300 mg) doses in a combination pill with emtricitabine (FTC, 200 mg) for six weeks...
  14. Glidden D, Mulligan K, McMahan V, Anderson P, Guanira J, Chariyalertsak S, et al. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. J Acquir Immune Defic Syndr. 2017;76:177-182 pubmed publisher
    ..of 498 participants in a randomized, placebo-controlled HIV prevention trial of oral coformulated TDF with emtricitabine (TDF/FTC, Truvada) for HIV pre-exposure prophylaxis (PrEP) enrolling a global sample of men who have sex with ..
  15. Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, et al. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. PLoS ONE. 2017;12:e0178942 pubmed publisher
    ..first-line regimen is tenofovir + lamivudine + efavirenz, but variations including nevirapine, stavudine or emtricitabine can be considered...
  16. Güerri Fernández R, Molina Morant D, Villar García J, Herrera S, González Mena A, Guelar A, et al. Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine. J Acquir Immune Defic Syndr. 2017;75:322-327 pubmed publisher
    ..To complement BMD-based predictions, these other techniques may also be used to identify patients with excess fracture risk. ..
  17. Vyas R, Reed A, Raper A, Zahurancik W, Wallenmeyer P, Suo Z. Structural basis for the D-stereoselectivity of human DNA polymerase ?. Nucleic Acids Res. 2017;45:6228-6237 pubmed publisher
    ..structures of hPol?, DNA and L-dCTP or the triphosphate forms of antiviral drugs lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) provide little structural evidence to suggest that hPol? follows the previously characterized ..
  18. Kruse L, Stover K, Henderson H. Perceptions of emtricitabine-tenofovir in HIV PrEP. HIV Clin. 2014;26:1, 4-7 pubmed
  19. Papavarnavas N, Manning K, Conrad F, Govender M, Maartens G. Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study. AIDS Res Ther. 2017;14:23 pubmed publisher
    ..9 [95% CI, 1.3-26.9]). We identified factors associated with LTFU of HCWs after occupational HIV exposure, which could be used to target interventions to improve follow-up. ..
  20. Sax P, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4:e154-e160 pubmed publisher
    ..estimated glomerular filtration rates of at least 70 mL per min, and HIV-1 genotypes showing sensitivity to emtricitabine and tenofovir...
  21. Carballo Dieguez A, BALAN I, Brown W, Giguere R, Dolezal C, Leu C, et al. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS ONE. 2017;12:e0181607 pubmed publisher
    ..2, randomized sequence, open-label, expanded safety and acceptability crossover study comparing 1) daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), 2) daily use of reduced-glycerin 1% tenofovir (RG-TFV) gel applied ..
  22. Lennox J, Landovitz R, Ribaudo H, Ofotokun I, Na L, Godfrey C, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161:461-71 pubmed publisher
    ..100 mg/d; raltegravir, 400 mg twice daily; or darunavir, 800 mg/d, with ritonavir, 100 mg/d, plus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d...